Bio B2B 〉 Selective Search Results
Your Selection Setting ：Investment；
Selective Search Results :
Pipeline & Platform 23 record(s)；
INNOPHARMAX has extensive pharmaceutical R&D experience, with former researchers who worked for the Medical and Pharmaceutical Industry Technology and Development Center in Taiwan (which is the most influential pharmaceutical technology developing organization funded by the Taiwan government), INNOPHARMAX's R&D team has been highly praised by numerous pharmaceutical
Homogeneous antibody drugs (CHO-H01, H02, H03)
A unique glycan structure was identified for monoclonal antibodies with improved activity. With the proprietary technology developed by CHO Pharma, the Fc-glycan structure of therapeutic antibodies can be engineered to a homogeneous glycoform, which displayed enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC), in vivo anti-tumor activities, and potential anti-inflammatory properties
TABP's transcriptional factor protein drugs are developed based on the fact that transcription factors can specifically act on the promoter of a gene. Comparable to monoclonal antibodies' specificity, the TABP's protein drugs can target to and regulate individual gene whose function people wish to change and by this means we can determined the proliferation and differentiation fate of cells. Advanced
Six Genomic Technology Platforms
IVD Sequencing & NGS analysisSNP genotyping analysisGene Chip analysisFunctional genomics analysisClinical genomics analysisBioinformatics analysis
Tmax of the current extended release tablets is too long, so children lose attention in learning when they start classes in the early morning.With both advantages of immediate and extended release, the unique multi-stages hot melt capsule releasing technology is able to become effective in early stage and sustainably release the drug to maintain the efficacy.The patented Oradur® formulation
The PixoTest® technology utilizes the lighting and image sensing module of the smartphone (or mobile device) to detect the color change reaction on the biochemical test strip (US patent granted). The image of the test strip is captured by the front camera of the smartphone and analyzed via the measurement algorithm to turn out a quantified or semi-quantified result. With the control on light
Physio-Chemical LaboratoryChemistry faculty of RRL conducts wide range of tests to evaluate the Physical-chemical properties of pure and formulated Agrochemicals in compliance with EEC, OECD, OPPTS and SANCO guidelines.We follow internationally accepted methods like FAO, WHO, AOAC and CIPAC with strict compliance to OECD principles of Good Laboratory Practices.The areas of expertise include:5
FB825 is a humanized monoclonal antibody that binds to the CεmX domain, leading to death of the membrane IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC) in a dosing-dependent manner. FB825 can stand alone as a monotherapy or in combination with Xolair for the treatment of allergic asthma and IgE-mediated diseases.
EG12014 Trastuzumab Biosimilar
Eirgenix aims to commercialize the first biosimilar product manufactured in Taiwan for the global market.Indication: HER2 Breast CancerExpected Product Launch: 2020Status: Phase 1 completed, BE established between EG12014 / EU & US HerceptinAdvantages of EG12014- The development of EG12014 follows EMA/FDA published guidance and past experience- EirGenix clinical study set up is considered an asset
Patented CMx® Platform
Circulating Tumor Cells as Biomarker for Early Cancer Detection. Saving Life, It's in Our Blood.The CMx® Platform uses a biomimetic, lipid-bilayer coated microﬂuidic chip to capture these rare cells in peripheral blood. For colonrectal cancer, the test can be useful in cases of non-compliance with recommended colonoscopies or messy stool tests, and as a supplemental screening.
The laser beams are dynamically focused on the surface of microarray slide based on the auto-focusing function using the focus error signal (FES). The auto-focusing of the laser beam is controlled using the focusing voice coil motor (VCM) to adjust the vertical distance between the objective lens and the surface of the sample slide on the basis of the FES (= (A+C)−(B+D), where A, B, C, and D
JHL1266 Denosumab Biosimilar
JHL1266 is a proposed biosimilar to denosumab, which is a monoclonal antibody used for treatment of a range of osteoporosis.
New combination for treating Sialorrhea
• Combination of two compounds with different Mechnism of Action to reduce the secreting of saliva.• First oral treatment for sialorrhoea of Parkinson's Disease.• Results of Phase IIa study, published in the 17th International Congress of Parkinson's Disease and Movement Disorders, shows efficacy and safety.
Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
CHO-A04 is a humanized monoclonal antibody targeting a novel carbohydrate antigen specifically and highly expressed on more than 10 cancer types, including triple negative breast cancer (TNBC) and pancreatic cancer. CHO-A04 kills cancer cells via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The proof-of-concept (POC) study for CHO-A04 has been well
CellMax SMSEQ® PlatformAnalytical specificity of ≥99.999%CellMax Life's liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify
JHL1152 Ipilimumab Biosimilar
JHL1152 is a proposed biosimilar to ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.
Isoniazid without liver toxicity
1. The common Tuberculosis (TB) drug Isoniazid has the most side effect of hepatotoxicity among all drugs, which is considered to be the major barrier of TB treatment.2. Isoniazid with new formulation has no hepatotoxicity due to the special excipient.
Dual-targeted bifunctional anti-flu drug (CHO-S05)
A novel series of dual-targeted bifunctional anti-flu drugs comprising of influenza virus inhibition and pro-inflammatory cytokine suppression are designed, synthesized and evaluated. In vitro and in vivo functional analyses have shown remarkable protection of cells and mice by oral administration against H1N1 & H5N1 influenza viruses.
JHL1255 Ustekinumab Biosimilar
JHL1255 is a proposed biosimilar to ustekinumab, a human monoclonal antibody that is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
Multiple-Phasic Release Technology (MPRT)
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
Glycan arrays and glycoprobes
Synthetic oligosaccharides and/or polysaccharides are immobilized on a solid supported in a spatially-defined arrangement to mimic the glycan expression on cell surface. The arrays of various glycans can be used for the diagnosis and prognosis of the disease such as cancer and infectious disease. They can also be used as research tools such as the validation of glycan binding protein and antibody,
JHL1178 Ramucirumab Biosimilar
JHL1178 is a proposed biosimilar to ramucirumab, a human IgG1 that binds to VEGFR2, which in turn blocks the natural ligands secreted by tumors, therefore can inhibit tumor angiogenesis.
Multi-day Transdermal Drug Delivery (MTDD)
Matrix type of design resolves API to form API/Adhesive patch, which is embedded in between Backing Layer and Release Liner. The API containing side of the patch can be adhered to the skin by tearing off the Release Liner. The patch can be designed as double layers for 1-2 days use or single layer for multiple days use.